Comparative Pharmacology
Head-to-head clinical analysis: RITALIN versus RITALIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RITALIN versus RITALIN LA.
RITALIN vs RITALIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), increasing their synaptic concentrations.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial: 5 mg orally twice daily (before breakfast and lunch); increase by 5-10 mg weekly; maximum 60 mg/day.
20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.
None Documented
None Documented
3-4 hours (immediate-release); 6-8 hours (sustained-release); clinical context: requires multiple daily dosing for sustained effect
Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation
Renal: 80-90% (as unchanged drug and metabolites, primarily ritalinic acid); Fecal: <1%; Biliary: minimal
Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2%
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant